BioInformant

Your Global Leader in Stem Cell Market Research

Home » Commence Bio

Commence Bio Receives 1st Patent for MSC1, An Innovative Cancer Immunotherapy Platform

By

In major news released this week, Commence Bio announced that the company has received its first patent for MSC1. Commence Bio is a pre-clinical stage biotechnology company that is based on the concept that cancer and other inflammatory conditions can be addressed by “rebooting patients’ immune systems” with a new class of medicinal stem cells, MSC1 and MSC2.

The company is now developing a therapeutic pipeline, as well as offering research products that include MSC1 and MSC2 cells and media. The concept around which the company is based is that its proprietary “stimulated Toll-like receptor technology” programs naïve MSCs to either a more potent anti-inflammatory phenotype, or a new pro-inflammatory, anti-tumor phenotype. [Read more…]

Commence Bio Focuses on Mesenchymal Stem Cells (MSCs) as Immunotherapies with New Website and Corporate ID

By

Commence Bio is an intriguing company that has recently entered the mesenchymal stem cell (MSC) marketplace. Commence Bio came across my  radar screen earlier this year right around the time that it announced the name change, as highlighted in the company press release below.

Specifically, Commence Bio is a pre-clinical stage biotechnology company that was “founded on the vision that cancer and inflammatory diseases can be optimally treated by rebooting patients’ immune systems with a new class of medicinal stem cells:  MSC1 & MSC2.” The company is  now developing a therapeutic pipeline, as well as offering research products (MSC1 and MSC2 cells and media). The concept around which the company is based is that its proprietary technology programs naïve MSCs so that they can localize to sites of immune dysfunction.

[Read more…]

BioInformant's World-Class Clients